Evaluating the Prognostic Significance of the Coefficient of Variation in Metabolic Heterogeneity from Baseline 18F-FDG PET/CT in Newly Diagnosed Diffuse Large B-Cell Lymphoma - Top-Institutions - MDSpire

Evaluating the Prognostic Significance of the Coefficient of Variation in Metabolic Heterogeneity from Baseline 18F-FDG PET/CT in Newly Diagnosed Diffuse Large B-Cell Lymphoma

  • By

  • Siqi Hu

  • Zijie Shen

  • Ting Yang

  • Yujie Xie

  • Qiong Zou

  • Ju Jiao

  • Muhua Cheng

  • Yong Zhang

  • February 23, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology-Oncology
    • Nuclear Medicine
    • Radiology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology-Oncology
    • Nuclear Medicine
    • Molecular Imaging

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology-Oncology
    • Nuclear Medicine
    • Radiology

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Hematology-Oncology
    • Nuclear Medicine
    • Radiology

  • #5

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology-Oncology
    • Nuclear Medicine
    • Radiology

Original Source(s)

Evaluating the Prognostic Significance of the Coefficient of Variation in Metabolic Heterogeneity from Baseline 18F-FDG PET/CT in Newly Diagnosed Diffuse Large B-Cell Lymphoma

  • by Siqi Hu, Zijie Shen, Ting Yang, Yujie Xie, Qiong Zou, Ju Jiao, Muhua Cheng, Yong Zhang

  • February 23, 2026

Related Content

Case Report: Synovial sarcoma with diffuse myxoid stroma and complete absence of epithelial differentiation in the extremity

Management of toxicities from antibody – drug conjugates in breast cancer

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”